vimarsana.com
Home
Live Updates
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 : vima
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 : vima
Samsung Bioepis Presents Post-hoc Analysis of Phase 3
Switching study conducted to evaluate whether switching from reference aflibercept to SB15 maintains comparable clinical efficacy and safetyPost-hoc...
Related Keywords
Amsterdam ,
Noord Holland ,
Netherlands ,
United States ,
American ,
Sergei Astakhov ,
Ranibizumab Biosimilar ,
Yeeun Kim ,
Aflibercept Biosimilar ,
Attila Vajas ,
Edward Wylegala ,
Samsung Bioepis ,
Mourad Farouk Rezk ,
Srinivasr Sadda ,
Wooree Choi ,
Srinivas Sadda ,
Seungkee Kim ,
Michal Orski ,
Hyejin Kim ,
Taehyung Kim ,
Jan Ernest ,
Sunil Patel ,
Jan Studnicka ,
Mario Bradvica ,
Neilm Bressler ,
Adrienne Csutak ,
Hyerin Jang ,
Cheolmin Yun ,
Twitter ,
Lifecycle Safety Team Leader At Samsung Bioepis ,
Linkedin ,
American Academy Of Ophthalmology ,
Samsung Bioepis Co Ltd ,
Association For Research ,
Vice President ,
Lifecycle Safety Team Leader ,
Global Medical ,
Biogen Biosimilars ,
Post Switching Efficacy ,
Safety Assessments ,
Proposed Aflibercept Biosimilar ,
Neovascular Age Related Macular Degeneration ,
Post Hoc Analysis ,
Free Paper Session ,
Min Sagong ,
Miroslav Veith ,
Mercy Yeeun Kim ,
Clinical Trial Comparing ,
Reference Aflibercept ,
Lajos Enyedi ,
Reference Product Lucentis ,
Randomized Clinical ,
Presentation Presented ,
Annual Meeting ,
American Academy ,
Clinical Outcomes ,
Approved Ranibizumab Biosimilar ,